Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 3226 AL 3240

Recent Advances in Multi-target Anti-Alzheimer Disease Compounds (2013 Up to the Present)

Wang N, Qiu P, Cui W, Yan X, Zhang B, He S.

Curr Med Chem. 2019;26(30):5684-5710. doi: 10.2174/0929867326666181203124102.

Tau Abnormalities and the Potential Therapy in Alzheimer's Disease

Almansoub HAMM, Tang H, Wu Y, Wang DQ, Mahaman YAR, Wei N, Almansob YAM, He W, Liu D.

J Alzheimers Dis. 2019;67(1):13-33. doi: 10.3233/JAD-180868.

Stem cell therapies for Alzheimer's disease: is it time?

Wang SM, Lee CU, Lim HK.

Curr Opin Psychiatry. 2019 Mar;32(2):105-116. doi: 10.1097/YCO.0000000000000478.

Death-Associated Protein Kinase 1 as a Promising Drug Target in Cancer and Alzheimer's Disease

Chen D, Zhou XZ, Lee TH.

Recent Pat Anticancer Drug Discov. 2019;14(2):144-157. doi: 10.2174/1574892814666181218170257.

Intranasal Delivery of Nanotherapeutics/ Nanobiotherapeutics for the Treatment of Alzheimer's Disease: A Proficient Approach

Dhas NL, Kudarha RR, Mehta TA.

Crit Rev Ther Drug Carrier Syst. 2019;36(5):373-447. doi: 10.1615/CritRevTherDrugCarrierSyst.2018026762.

A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease

Panza F, Lozupone M, Logroscino G, Imbimbo BP.

Nat Rev Neurol. 2019 Feb;15(2):73-88. doi: 10.1038/s41582-018-0116-6.

A pilot study on the effect of lactoferrin on Alzheimer's disease pathological sequelae: Impact of the p-Akt/PTEN pathway

Mohamed WA, Salama RM, Schaalan MF.

Biomed Pharmacother. 2019 Mar;111:714-723. doi: 10.1016/j.biopha.2018.12.118. Epub 2019 Jan 3.

Multidisciplinary approaches for targeting the secretase protein family as a therapeutic route for Alzheimer's disease

Schaduangrat N, Prachayasittikul V, Choomwattana S, Wongchitrat P, Phopin K, Suwanjang W, Malik AA, Vincent B, Nantasenamat C.

Med Res Rev. 2019 Sep;39(5):1730-1778. doi: 10.1002/med.21563. Epub 2019 Jan 9.

Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease

Madav Y, Wairkar S, Prabhakar B.

Brain Res Bull. 2019 Mar;146:171-184. doi: 10.1016/j.brainresbull.2019.01.004. Epub 2019 Jan 8.

Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?

Panza F, Lozupone M, Seripa D, Imbimbo BP.

Ann Neurol. 2019 Mar;85(3):303-315. doi: 10.1002/ana.25410. Epub 2019 Jan 28.

Procyanidins and Alzheimer's Disease

Zhao S, Zhang L, Yang C, Li Z, Rong S.

Mol Neurobiol. 2019 Aug;56(8):5556-5567. doi: 10.1007/s12035-019-1469-6. Epub 2019 Jan 16.

The Promises and Challenges of Erythropoietin for Treatment of Alzheimer's Disease

Sun J, Martin JM, Vanderpoel V, Sumbria RK.

Neuromolecular Med. 2019 Mar;21(1):12-24. doi: 10.1007/s12017-019-08524-y. Epub 2019 Jan 17.

A short perspective on the long road to effective treatments for Alzheimer's disease

Reynolds DS.

Br J Pharmacol. 2019 Sep;176(18):3636-3648. doi: 10.1111/bph.14581. Epub 2019 Mar 1.

Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule

Poddar SK, Sifat AE, Haque S, Nahid NA, Chowdhury S, Mehedi I.

Biomolecules. 2019 Jan 21;9(1):34. doi: 10.3390/biom9010034.

Recent Expansions on Cellular Models to Uncover the Scientific Barriers Towards Drug Development for Alzheimer's Disease

Dubey SK, Ram MS, Krishna KV, Saha RN, Singhvi G, Agrawal M, Ajazuddin, Saraf S, Saraf S, Alexander A.

Cell Mol Neurobiol. 2019 Mar;39(2):181-209. doi: 10.1007/s10571-019-00653-z. Epub 2019 Jan 23.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias